Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital-Reference-Cited by-同舟云学术

Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital

Published:2018 Issue:5 Volume:35 Page:390
ISSN:0970-2113
Container-title:Lung India
language:en
Short-container-title:Lung India

Author:

Babu Koyyala VenkataPradeep,Batra Ullas,Jain Parveen,Sharma Mansi,Goyal Pankaj,Medisetty Pavani,Jajodia Ankush,Maheshwari UdipDilip

Publisher

Medknow

Subject

Pulmonary and Respiratory Medicine

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years;Cancer Research, Statistics, and Treatment;2024-01

2. The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare;Cancers;2022-07-19

3. All-in-one approaches for rapid and highly specific quantifcation of single nucleotide polymorphisms based on ligase detection reaction using molecular beacons as turn-on probes;Talanta;2021-03

4. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review);International Journal of Oncology;2021-01-07

5. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India;Current Problems in Cancer;2020-06